BACKGROUND: Little is known regarding the health-related quality of life (HRQL) trajectory of children with sickle cell disease or thalassemia ("hemoglobinopathies") following hematopoietic stem cell transplantation (HSCT). PROCEDURES: We serially evaluated the HRQL of 13 children with hemoglobinopathies who received HSCT during two prospective multi-center studies using the Child Health Ratings Inventories (CHRIs). The HRQL scores among children with hemoglobinopathies, as reported separately by the children and their parents were compared using repeated measures models to scores of a comparison group of children receiving HSCT for malignancies or severe aplastic anemia. RESULTS: The sample included 13 children with hemoglobinopathies (median age: 8 years, range 5-18) and 268 children in the comparison group (median age: 11 years, range 5-18). There were similar rates of early infection, chronic graft versus host disease, and all-cause mortality between the two groups. There was no significant difference in recovery to baseline scores for physical, emotional, and role functioning by 3 months for either group. Children with hemoglobinopathies had higher HRQL scores for physical (beta = 12, se = 5.5, P = 0.01) and baseline emotional functioning (beta = 11.6, se = 5.5, P = 0.03) than the comparison group. For all domains for both groups, parent reports demonstrated a nadir at 45 days with recovery to baseline by 3 months following transplant. Children's ratings were higher than those of their parents in both diagnostic groups. CONCLUSIONS: Children with hemoglobinopathies had higher physical and emotional functioning scores prior to HSCT and experienced a similar pattern of recovery to their baseline functioning by 3 months post-HSCT when compared to children receiving HSCT for acquired conditions.
BACKGROUND: Little is known regarding the health-related quality of life (HRQL) trajectory of children with sickle cell disease or thalassemia ("hemoglobinopathies") following hematopoietic stem cell transplantation (HSCT). PROCEDURES: We serially evaluated the HRQL of 13 children with hemoglobinopathies who received HSCT during two prospective multi-center studies using the Child Health Ratings Inventories (CHRIs). The HRQL scores among children with hemoglobinopathies, as reported separately by the children and their parents were compared using repeated measures models to scores of a comparison group of children receiving HSCT for malignancies or severe aplastic anemia. RESULTS: The sample included 13 children with hemoglobinopathies (median age: 8 years, range 5-18) and 268 children in the comparison group (median age: 11 years, range 5-18). There were similar rates of early infection, chronic graft versus host disease, and all-cause mortality between the two groups. There was no significant difference in recovery to baseline scores for physical, emotional, and role functioning by 3 months for either group. Children with hemoglobinopathies had higher HRQL scores for physical (beta = 12, se = 5.5, P = 0.01) and baseline emotional functioning (beta = 11.6, se = 5.5, P = 0.03) than the comparison group. For all domains for both groups, parent reports demonstrated a nadir at 45 days with recovery to baseline by 3 months following transplant. Children's ratings were higher than those of their parents in both diagnostic groups. CONCLUSIONS:Children with hemoglobinopathies had higher physical and emotional functioning scores prior to HSCT and experienced a similar pattern of recovery to their baseline functioning by 3 months post-HSCT when compared to children receiving HSCT for acquired conditions.
Authors: H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas Journal: Transplantation Date: 1974-10 Impact factor: 4.939
Authors: S I Bearman; F R Appelbaum; C D Buckner; F B Petersen; L D Fisher; R A Clift; E D Thomas Journal: J Clin Oncol Date: 1988-10 Impact factor: 44.544
Authors: M C Walters; M Patience; W Leisenring; J R Eckman; J P Scott; W C Mentzer; S C Davies; K Ohene-Frempong; F Bernaudin; D C Matthews; R Storb; K M Sullivan Journal: N Engl J Med Date: 1996-08-08 Impact factor: 91.245
Authors: O S Platt; D J Brambilla; W F Rosse; P F Milner; O Castro; M H Steinberg; P P Klug Journal: N Engl J Med Date: 1994-06-09 Impact factor: 91.245
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: G Lucarelli; M Galimberti; P Polchi; E Angelucci; D Baronciani; C Giardini; P Politi; S M Durazzi; P Muretto; F Albertini Journal: N Engl J Med Date: 1990-02-15 Impact factor: 91.245
Authors: Agatha M Gallo; Crystal Patil; Tokunbo Adeniyi; Lewis L Hsu; Damiano Rondelli; Santosh Saraf Journal: West J Nurs Res Date: 2018-04-06 Impact factor: 1.967
Authors: Ashley E Neal; Christian Stopp; David Wypij; David C Bellinger; Carolyn Dunbar-Masterson; David R DeMaso; Jane W Newburger Journal: J Pediatr Date: 2014-10-28 Impact factor: 4.406
Authors: Claudia Di Lorenzo Oliveira; Shannon Kelly; Cesar de Almeida-Neto; Anna Barbara Carneiro-Proietti; Fabiana Chagas Camargos Piassi; Tassila Salomon; Miriam V Flor-Park; Claudia Maximo; Daniela Werneck Rodrigues; Rosimere Afonso Mota; Carolina Miranda Teixeira; Paula Loureiro; Ester Cerdeira Sabino; Brian Custer Journal: Pediatr Hematol Oncol Date: 2019-09-06 Impact factor: 1.969
Authors: Katherine E Heinze; Angie Mae Rodday; Marie T Nolan; Kristin Bingen; Mary Jo Kupst; Sunita K Patel; Karen Syrjala; Lynnette Harris; Christopher Recklitis; Lisa Schwartz; Stella Davies; Eva C Guinan; Robert Noll; Grace Chang; Susan K Parsons Journal: Health Qual Life Outcomes Date: 2015-04-09 Impact factor: 3.186